PT  - JOURNAL ARTICLE
AU  - Grady, Connor B
AU  - Bhattacharjee, Bornali
AU  - Silva, Julio
AU  - Jaycox, Jillian
AU  - Lee, Lik Wee
AU  - Monteiro, Valter Silva
AU  - Sawano, Mitsuaki
AU  - Massey, Daisy
AU  - Caraballo, César
AU  - Gehlhausen, Jeff R.
AU  - Tabachnikova, Alexandra
AU  - Mao, Tianyang
AU  - Lucas, Carolina
AU  - Peña-Hernandez, Mario A.
AU  - Xu, Lan
AU  - Tzeng, Tiffany J.
AU  - Takahashi, Takehiro
AU  - Herrin, Jeph
AU  - Güthe, Diana Berrent
AU  - Akrami, Athena
AU  - Assaf, Gina
AU  - Davis, Hannah
AU  - Harris, Karen
AU  - McCorkell, Lisa
AU  - Schulz, Wade L
AU  - Grffin, Daniel
AU  - Wei, Hannah
AU  - Ring, Aaron M
AU  - Guan, Leying
AU  - Cruz, Charles Dela
AU  - Iwasaki, Akiko
AU  - Krumholz, Harlan M
TI  - Impact of COVID-19 vaccination on symptoms and immune phenotypes in vaccine-naïve individuals with Long COVID
AID  - 10.1101/2024.01.11.24300929
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.01.11.24300929
4099  - http://medrxiv.org/content/early/2024/01/12/2024.01.11.24300929.short
4100  - http://medrxiv.org/content/early/2024/01/12/2024.01.11.24300929.full
AB  - Background Long COVID contributes to the global burden of disease. Proposed root cause hypotheses include the persistence of SARS-CoV-2 viral reservoir, autoimmunity, and reactivation of latent herpesviruses. Patients have reported various changes in Long COVID symptoms after COVID-19 vaccinations, leaving uncertainty about whether vaccine-induced immune responses may alleviate or worsen disease pathology.Methods In this prospective study, we evaluated changes in symptoms and immune responses after COVID-19 vaccination in 16 vaccine-naïve individuals with Long COVID. Surveys were administered before vaccination and then at 2, 6, and 12 weeks after receiving the first vaccine dose of the primary series. Simultaneously, SARS-CoV-2-reactive TCR enrichment, SARS-CoV-2-specific antibody responses, antibody responses to other viral and self-antigens, and circulating cytokines were quantified before vaccination and at 6 and 12 weeks after vaccination.Results Self-report at 12 weeks post-vaccination indicated 10 out of 16 participants had improved health, 3 had no change, 1 had worse health, and 2 reported marginal changes. Significant elevation in SARS-CoV-2-specific TCRs and Spike protein-specific IgG were observed 6 and 12 weeks after vaccination. No changes in reactivities were observed against herpes viruses and self-antigens. Within this dataset, higher baseline sIL-6R was associated with symptom improvement, and the two top features associated with non-improvement were high IFN-β and CNTF, among soluble analytes.Conclusions Our study showed that in this small sample, vaccination improved the health or resulted in no change to the health of most participants, though few experienced worsening. Vaccination was associated with increased SARS-CoV-2 Spike protein-specific IgG and T cell expansion in most individuals with Long COVID. Symptom improvement was observed in those with baseline elevated sIL-6R, while elevated interferon and neuropeptide levels were associated with a lack of improvement.Plain language summary The impact of the COVID-19 vaccine on vaccine-naïve individuals suffering from Long COVID is uncertain. This study assessed the experience and immune signatures of 16 unvaccinated participants with Long COVID. A total of 10 participants had improved health status after vaccination, and one person reported only worsening health. As expected, vaccination increased immune cells and antibodies against the viral spike protein. Immune signatures may prove to be predictors of health status after vaccination. However, given the small number of participants, these initial findings need further validation.Competing Interest StatementThe authors have declared no competing interest.Clinical Protocols https://www.medrxiv.org/content/10.1101/2021.07.21.21260391v2.full Funding StatementThis work was supported in part by funds from Fred Cohen and Carolyn Klebanoff and by grants from National Institute of Allergy and Infectious Diseases (R01AI157488 to A.I.), the Howard Hughes Medical Institute Collaborative COVID-19 Initiative (to A.I.), and the Howard Hughes Medical Institute (to A.I.). J. J., T.T., and B. B. received research support from Yale University from the Food and Drug Administration for the Yale-Mayo Clinic Center of Excellence in Regulatory Science and Innovation (CERSI) (U01FD005938).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institutional Review Board of Yale University gave ethical approval for this work (IRB #2000030423)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors